Glaxo, Genmab say disappointed with study of lymphoma treatment

May 19, 2014 10:47 PM

3 0

(Reuters) - GlaxoSmithKline and Danish biotech company Genmab said disappointing results from a study on treating relapsed lymphoma with their ofatumumab drug meant it was unlikely they would seek its regulatory approval.

A head-to-head phase III study of ofatumumab and another drug to fight the fast-growing blood cancer failed to meet the companies' goals. Results showed no significant difference in progression free survival (PFS) between one treatment arm and the other, the companies said in a statement late on Mon...

Read more

To category page

Loading...